Publications by authors named "Samira Marin-Romero"
Article Synopsis
- Detecting hidden cancers in patients with unexplained venous thromboembolism (VTE) is challenging, and this study sought to explore how coagulation-related biomarkers could help.
- A study involving 214 patients with unprovoked VTE measured several biomarkers at diagnosis, finding that sP-selectin levels were significantly higher in patients with occult cancer.
- Combining high levels of sP-selectin and D-dimer can potentially identify occult cancer with up to 91% specificity, indicating these biomarkers may be useful in clinical settings, although more research is needed.
Article Synopsis
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious complication that can occur after acute pulmonary embolism (PE), and this study evaluated a screening program for its detection among PE survivors.
- The study involved contacting patients diagnosed with acute PE two years prior to assess for symptoms like dyspnoea, leading to further testing for CTEPH diagnosis.
- The results showed that the symptom screening led to a significant increase in CTEPH diagnoses, highlighting the importance of follow-up protocols for better patient outcomes.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative rare disease characterized by symptoms and signs in the upper and lower motor neurons, leading to progressive neuro-degeneration and muscle atrophy. Our objective was to analyse the quality of life (QoL) in patients with ALS and compare with general population and with patients with cancer. Prospective study from consecutive ALS patients in one center.
View Article and Find Full Text PDFBackground: Clinical practice guidelines recommend that patients with incidental venous thromboembolism (VTE) receive the same anticoagulant therapy as those with symptomatic VTE. We aimed to compare the rate of complications between cancer patients with incidental and symptomatic VTE through a long-term follow-up cohort.
Methods: We performed a analysis of prospective studies of cancer patients with VTE between 2008 and 2019, with the primary outcome of rates of recurrent VTE and clinically relevant bleeding (CRB) in incidental and symptomatic VTE groups.
Background: Clinical guidelines suggest continuing anticoagulation therapy for >6 months for patients with active cancer and venous thromboembolism (VTE). However, data regarding the safety of its discontinuation are scarce.
Objectives: To valuate the risk factors and the incidence of recurrent VTE 6 months after the discontinuation of anticoagulation therapy in patients with cancer-associated thrombosis (CAT).
Background: Clinical guidelines indicate that in patients with cancer-associated thrombosis (CAT), anticoagulant treatment should be continued beyond 6 months as long as the cancer is active. We aimed to analyse the safety of low-molecular-weight heparin (LMWH) beyond 12 months in patients with CAT.
Methods: We performed a post hoc analysis of consecutive CAT patients from October 2008 to December 2019.
Article Synopsis
- Anemia is a common issue among cancer patients, negatively affecting their quality of life (QoL) and related symptoms, though its exact impact has been unclear due to varying definitions in past studies.
- Researchers conducted a detailed analysis using specific QoL questionnaires to assess the impact of anemia on cancer patients within a multicenter study from 2015-2018, which included 365 participants.
- Results showed that cancer patients with anemia reported significantly lower global health status and more severe symptoms compared to those without anemia, indicating a clinically and statistically worse QoL for anemia sufferers.
In symptomatic acute pulmonary embolism (PE), the presence of deep vein thrombosis (DVT) is a risk factor for 30- and 90-day mortality. In patients with cancer and incidental PE, the prognostic effect of concomitant incidental DVT is unknown. In this retrospective study, we examined the effect of incidental DVT on all-cause mortality in such patients.
View Article and Find Full Text PDFThe relationship between venous thromboembolism (VTE) and cancer has become an area of intense debate due to the importance and the potential benefits of the identification of occult cancer following the diagnosis of unprovoked VTE. At present, extended screening is not recommended in patients with unprovoked VTE. However, if we were able to identify a group at greater risk of presenting cancer during follow-up, these patients would benefit from extended screening.
View Article and Find Full Text PDFVenous thromboembolism (VTE) is a growing concern in patients with cancer. Current guidelines recommend that cancer patients with VTE should receive anticoagulation for at least 3-6 months. However, the question as to whether anticoagulants should be continued after 3 to 6 months of treatment remains open.
View Article and Find Full Text PDFRisk Of Recurrence After Withdrawal Of Anticoagulation In Patients With Unprovoked Venous Thromboembolism: External Validation Of The Vienna Nomogram And The Dash Prediction Score.
Arch Bronconeumol (Engl Ed)
December 2019
Introduction: Scales for predicting venous thromboembolism (VTE) recurrence are useful for deciding the duration of the anticoagulant treatment. Although there are several scales, the most appropriate for our setting has not been identified. For this reason, we aimed to validate the DASH prediction score and the Vienna nomogram at 12 months.
View Article and Find Full Text PDFReply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'.
Br J Cancer
February 2019
D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis.
Br J Cancer
October 2018
Background: Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT.
Methods: Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued.